AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-19. **(Cancelled)**

20. **(Currently amended)** The method of claim ~~19~~ 55, wherein the cyclosporine is administered as a dry powder in combination with a propellant.

21. **(Currently amended)** The method of claim ~~19~~ 55, wherein the cyclosporine is dissolved in an organic solvent.

22. **(Currently amended)** The method of claim ~~19~~ 55, 20 or 21 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 15 and 30 mg in a lung.

23. **(Cancelled)**

24. **(Currently amended)** The method of claim ~~19~~ 55, 20 or 21 wherein the aerosolized composition is co-administered with an effective amount of one or more other agent selected from the group consisting of an immunosuppressive agent and an anti-inflammatory reagent.

25-48. **(Cancelled)**

49. **(Currently amended)** The method of claim ~~19~~ 55, wherein the first administration occurs within 31 days of transplantation.

50. **(Previously Presented)** The method of claim 49, wherein the first administration occurs within 10 days of transplantation.

51.-54 **(Cancelled)**

55. **(New)** A method for inhibiting chronic graft rejection in a human lung transplant recipient, comprising administering to the transplant recipient, prior to the development of refractory graft rejection, an aerosolized composition comprising an effective dose of cyclosporine, wherein said dose is less systemically toxic than the same dose administered orally, and wherein chronic graft rejection is inhibited in the transplant recipient.

56. **(New)** The method of claim 55, wherein the cyclosporine is administered as a dry powder.

57. **(New)** The method of claim 55, wherein the cyclosporine is dissolved in ethanol.